Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $45.00 by Analysts at Wells Fargo & Company

Key Points

• Wells Fargo cut Ultragenyx Pharmaceutical’s price target from $47 to $45 while maintaining an “overweight” rating; the new target implies approximately 77.8% upside from the reported $25.31 share price.
• Analyst sentiment remains generally positive, with a MarketBeat consensus rating of “Moderate Buy” and an average price target of $57.82, despite mixed revisions from firms including Guggenheim, Wedbush and Barclays.
• Ultragenyx reported second-quarter revenue of $214 million, up 28.5% year over year and above estimates, while its loss of $0.90 per share was narrower than expected; management reaffirmed 2026 revenue guidance of $730 million to $760 million.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price reduced by analysts at Wells Fargo & Company from $47.00 to $45.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price target points to a potential upside of 77.80% from the company's current price.

Several other equities analysts have also issued reports on the company. Wedbush lowered their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Wednesday, May 6th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a "strong sell" rating to a "sell" rating in a research note on Saturday, June 6th. Guggenheim cut their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday. Royal Bank Of Canada raised their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an "outperform" rating in a research report on Tuesday, July 7th. Finally, Barclays decreased their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating for the company in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $57.82.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded down $0.50 during mid-day trading on Wednesday, hitting $25.31. 1,030,734 shares of the company's stock were exchanged, compared to its average volume of 2,219,865. Ultragenyx Pharmaceutical has a one year low of $18.29 and a one year high of $39.89. The business has a fifty day moving average price of $27.77 and a 200 day moving average price of $24.76. The company has a market cap of $2.49 billion, a PE ratio of -4.14 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.32. The company had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm's revenue for the quarter was up 28.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.17) EPS. On average, equities analysts forecast that Ultragenyx Pharmaceutical will post -4.53 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Shehnaaz Suliman sold 5,740 shares of the firm's stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director directly owned 27,951 shares of the company's stock, valued at approximately $702,129.12. This trade represents a 17.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director directly owned 21,095 shares in the company, valued at $528,429.75. This represents a 8.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 14,292 shares of company stock worth $351,644 over the last quarter. Company insiders own 5.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company's stock valued at $8,414,000 after acquiring an additional 29,984 shares during the last quarter. Creative Planning bought a new stake in Ultragenyx Pharmaceutical in the second quarter worth $454,000. American Century Companies Inc. purchased a new stake in Ultragenyx Pharmaceutical during the second quarter valued at $366,000. M&T Bank Corp raised its stake in Ultragenyx Pharmaceutical by 19.7% during the second quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company's stock valued at $263,000 after purchasing an additional 1,192 shares in the last quarter. Finally, Amundi lifted its position in Ultragenyx Pharmaceutical by 1,560.4% during the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company's stock valued at $3,913,000 after purchasing an additional 93,189 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported a second-quarter loss of $0.90 per share, beating the consensus estimate for a $1.22 loss and improving from a $1.17 loss in the year-ago quarter. Revenue rose 28.5% year over year to $214 million, exceeding analysts’ $183.08 million estimate. Ultragenyx Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Product performance was led by Crysvita revenue of $156 million and Dojolvi revenue of $27 million, supporting the company’s revenue growth. Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Management reaffirmed 2026 revenue guidance of $730 million to $760 million and expects combined research and development and selling, general and administrative expenses to be flat to slightly lower than in 2025. Ultragenyx remains on track for profitability in 2027. Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Investors have multiple second-half catalysts to watch, including two FDA PDUFA decisions and pivotal Phase 3 Aspire data for GTX-102 in Angelman syndrome. Ultragenyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Guggenheim lowered its price target from $43 to $35, although it maintained a Buy rating. The revised target still implies meaningful potential upside but signals more cautious valuation expectations. Guggenheim Price Target Update

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source